Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 259 (7), 1312-6

Anti-voltage-gated Potassium Channel Kv1.4 Antibodies in Myasthenia Gravis


Anti-voltage-gated Potassium Channel Kv1.4 Antibodies in Myasthenia Gravis

Fredrik Romi et al. J Neurol.


Myasthenia gravis (MG) is an autoimmune disease characterized by skeletal muscle weakness mainly caused by acetylcholine receptor antibodies. MG can be divided into generalized and ocular, and into early-onset (<50 years of age) and late-onset (≥50 years of age). Anti-Kv1.4 antibodies targeting α-subunits (Kv1.4) of the voltage-gated potassium K(+) channel occurs frequently among patients with severe MG, accounting for 18% of a Japanese MG population. The aim of this study was to characterize the clinical features and serological associations of anti-Kv1.4 antibodies in a Caucasian MG population with mild and localized MG. Serum samples from 129 Caucasian MG patients with mainly ocular symptoms were tested for the presence of anti-Kv1.4 antibodies and compared to clinical and serological parameters. There were 22 (17%) anti-Kv1.4 antibody-positive patients, most of them women with late-onset MG, and all of them with mild MG. This contrasts to the Japanese anti-Kv1.4 antibody-positive patients who suffered from severe MG with bulbar symptoms, myasthenic crisis, thymoma, myocarditis and prolonged QT time on electrocardiography, despite equal anti-Kv1.4 antibody occurrence in both populations. No other clinical or serological parameters influenced anti-Kv1.4 antibody occurrence.

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles


    1. Lancet Neurol. 2009 May;8(5):475-90 - PubMed
    1. J Neuroimmunol. 2011 Jan;230(1-2):148-52 - PubMed
    1. Neurology. 2008 May 13;70(20):1883-90 - PubMed
    1. J Neuroimmunol. 2010 Aug 25;225(1-2):180-3 - PubMed
    1. Nat Med. 2001 Mar;7(3):365-8 - PubMed

Publication types